Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis-Reference-Cited by-同舟云学术

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Shulgin Boris¹,Kosinsky Yuri¹,Omelchenko Andrey¹,Chu Lulu²,Mugundu Ganesh³,Aksenov Sergey³,Pimentel Rodrigo⁴,DeYulia Garrett⁴,Kim Geoffrey⁵,Peskov Kirill¹⁶^ORCID,Helmlinger Gabriel⁷^ORCID

Affiliation:

1. M&S Decisions LLC, Moscow, Russia

2. PK Sciences Modeling & Simulation, Novartis Institutes of BioMedical Research, Cambridge, MA, USA

3. Clinical Pharmacology & Quantitative Pharmacology, R&D BioPharmaceuticals, AstraZeneca, Waltham, MA, USA

4. Medical Affairs, AstraZeneca, Gaithersburg, MD, USA

5. Applied Innovation, BeiGene, Cambridge, MA, USA

6. I.M.Sechenov first Moscow State Medical University of the Russian Ministry of Health, Moscow, Russia

7. Clinical Pharmacology & Toxicology, Obsidian Therapeutics, Cambridge, MA, USA

Funder

AstraZeneca

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1748982

Reference97 articles.

1. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

3. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

5. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitigating non-genetic resistance to checkpoint inhibition based on multiple states of immune exhaustion;npj Systems Biology and Applications;2024-02-09

2. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit;Cancer Science;2024-01-22

3. Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy;Journal of Controlled Release;2024-01

4. Real-world efficacy and safety of low-dose pembrolizumab in patients with advanced and refractory gynecologic cancers;Journal of the Formosan Medical Association;2023-10